Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at...

Full description

Bibliographic Details
Main Authors: Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Ana Lopez de la Guia, Enrique Bengoechea, Luis Palomera, Felipe de Arriba, Jose Mariano Hernandez, Miquel Granell, Francisco Javier Peñalver, Ramon Garcia-Sanz, Juan Besalduch, Yolanda Gonzalez, Rafael Benigno Martinez, Miguel Teodoro Hernandez, Norma C Gutierrez, Paloma Puerta, Antonio Valeri, Bruno Paiva, Joan Blade, Maria-Victoria Mateos, Jesus San Miguel, Juan Jose Lahuerta, Joaquin Martinez-Lopez, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6128544?pdf=render